The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy

Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and nece...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 23; no. 1; pp. 1 - 10
Main Authors Tsai, Tsung-Han, Su, Po-Jung, Huang, Shih-Yu, Kuo, Ming-Chun, Lin, Chang-Ting, Wu, Chia-Che, Luo, Hao-Lun, Chen, Chien-Hsu, Chou, Chih-Chi, Liu, Ting-Ting, Huang, Chun-Chieh, Tsai, Kai-Lung, Su, Yu-Li
Format Journal Article
LanguageEnglish
Published London BioMed Central 15.09.2023
BioMed Central Ltd
BMC
Subjects
Analysis
Biomedical and Life Sciences
Biomedicine
Bladder cancer
Cancer
Cancer Research
Carcinoma
Care and treatment
Chemotherapy
Development and progression
FDA approval
Genetic aspects
Genetic variation
Health Promotion and Disease Prevention
Hemoglobin
Immune checkpoint inhibitors
Medical prognosis
Medicine/Public Health
Metastases
Metastasis
Metastatic urothelial carcinoma
Monoclonal antibodies
Multivariate analysis
Oncology
Patient outcomes
Patients
Performance evaluation
Prognosis
Real-world data
Response rates
Statistical significance
Surgical Oncology
Survival
Survival analysis
Urothelial carcinoma
Variant histology
United States
Taiwan
Immune checkpoint inhibitors
Variant histology
Metastatic urothelial carcinoma
Real-world data
Online AccessGet full text
ISSN1471-2407
1471-2407
DOI10.1186/s12885-023-11398-w

Cover

Abstract Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research. Method We conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data. Result A total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004). Conclusion The use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC.
AbstractList While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research.BACKGROUNDWhile the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research.We conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data.METHODWe conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data.A total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004).RESULTA total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004).The use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC.CONCLUSIONThe use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC.
While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research. We conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data. A total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004). The use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC.
Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research. Method We conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data. Result A total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004). Conclusion The use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC. Keywords: Metastatic urothelial carcinoma, Variant histology, Immune checkpoint inhibitors, Real-world data
Abstract Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research. Method We conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data. Result A total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004). Conclusion The use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC.
Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research. Method We conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data. Result A total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004). Conclusion The use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC.
BackgroundWhile the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research.MethodWe conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data.ResultA total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004).ConclusionThe use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC.
ArticleNumber 871
Audience Academic
Author Wu, Chia-Che
Liu, Ting-Ting
Su, Po-Jung
Kuo, Ming-Chun
Huang, Chun-Chieh
Luo, Hao-Lun
Chou, Chih-Chi
Chen, Chien-Hsu
Huang, Shih-Yu
Tsai, Tsung-Han
Lin, Chang-Ting
Su, Yu-Li
Tsai, Kai-Lung
Author_xml – sequence: 1
  givenname: Tsung-Han
  surname: Tsai
  fullname: Tsai, Tsung-Han
  organization: Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 2
  givenname: Po-Jung
  surname: Su
  fullname: Su, Po-Jung
  organization: Division of Hematology Oncology, Chang Gung Memorial Hospital at Linkou and College of Medicine, Chang Gung University
– sequence: 3
  givenname: Shih-Yu
  surname: Huang
  fullname: Huang, Shih-Yu
  organization: Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 4
  givenname: Ming-Chun
  surname: Kuo
  fullname: Kuo, Ming-Chun
  organization: Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 5
  givenname: Chang-Ting
  surname: Lin
  fullname: Lin, Chang-Ting
  organization: Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 6
  givenname: Chia-Che
  surname: Wu
  fullname: Wu, Chia-Che
  organization: Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 7
  givenname: Hao-Lun
  surname: Luo
  fullname: Luo, Hao-Lun
  organization: Department of Urology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 8
  givenname: Chien-Hsu
  surname: Chen
  fullname: Chen, Chien-Hsu
  organization: Department of Urology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 9
  givenname: Chih-Chi
  surname: Chou
  fullname: Chou, Chih-Chi
  organization: Department of Pathology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University
– sequence: 10
  givenname: Ting-Ting
  surname: Liu
  fullname: Liu, Ting-Ting
  organization: Department of Pathology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University
– sequence: 11
  givenname: Chun-Chieh
  surname: Huang
  fullname: Huang, Chun-Chieh
  organization: Department of Radiation Oncology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 12
  givenname: Kai-Lung
  surname: Tsai
  fullname: Tsai, Kai-Lung
  organization: Department of Colorectal Surgery, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
– sequence: 13
  givenname: Yu-Li
  surname: Su
  fullname: Su, Yu-Li
  email: yolisu@mac.com
  organization: Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Genomic & Proteomic Core Laboratory, Department of Medical Research
BookMark eNp9kktr3DAUhU1JaR7tH-hKUCjpwqkkPySvSgh9BAKFNl0LWXNt39SWppI8aX5Q_2flTGgyoQQvbKTvnMs9PofZnnUWsuw1oyeMyfp9YFzKKqe8yBkrGplfP8sOWClYzksq9h5872eHIVxRyoSk8kW2XwjBqqQ5yP5cDkDW3vXWhYiGBOwtdmi0NUBcRwYM0Y2uT1cb7VHbSJwlYfYb3OiRuDkaN0EgaMlaRwQbA7nGOJAJog5RL56zd3GAERNvtDdo3aSJBwO4QdsTnKbZAjEDmJ9rh2kC2gFbjM6TpPN6ffMye97pMcCru_dR9uPTx8uzL_nF18_nZ6cXuakrGnPBJDDT8iZtSlu-otDIVpemakRRN7xtDNSmo5Sbru3aCpqukVUrmqqUsuEdK46y863vyukrtfY4aX-jnEZ1e-B8r7RPK42gGK1ZU_NKcknLcpksyqKuDXBDS2lM8vqw9VrP7QQrk6Lxetwx3b2xOKjebZJzRUtRF8nh-M7Bu18zhKgmDAbGUVtwc1Bc1tXyQyuR0DeP0Cs3e5uyuqUKWdBa3lO9Thug7VwabBZTdSrqlIIomjpRJ_-h0rOCCU2qYIfpfEfwbkeQmAi_Y6_nENT592-77NsH7AB6jENw4xzR2bAL8i1ovAvBQ_cvOUbVUn-1rb9K9Ve39VfXSSQfiQwuHXRLwjg-LS220pDm2B78fYJPqP4CYEEchQ
CitedBy_id crossref_primary_10_1016_j_clgc_2024_102273
crossref_primary_10_1200_EDBK_438640
Cites_doi 10.1016/j.euf.2019.09.003
10.2147/OTT.S290113
10.1111/bju.15510
10.1111/bju.15428
10.1186/s12894-023-01210-z
10.1038/s41591-020-1086-y
10.1097/JU.0000000000000761
10.1038/nrurol.2017.125
10.1159/000502174
10.1016/j.clgc.2022.05.001
10.1371/journal.pone.0129268
10.1016/j.ejca.2005.08.032
10.1200/JCO.18.01148
10.1200/JCO.2000.18.17.3068
10.1200/JCO.2019.37.7_suppl.451
10.1016/j.eururo.2020.01.003
10.3389/fimmu.2021.734293
10.1016/j.eururo.2019.10.026
10.1101/mcs.a006151
10.1016/S0140-6736(20)30230-0
10.1016/j.clgc.2020.07.011
10.1016/j.clgc.2017.07.008
10.26508/lsa.202000737
10.3322/caac.21660
10.1200/JCO.1999.17.10.3173
10.1016/j.urolonc.2019.09.025
10.1371/journal.pone.0171701
10.5402/2011/545241
10.1097/JU.0000000000002799
10.1200/EDBK_201193
10.1016/j.clgc.2020.10.002
10.1111/bju.15984
10.1016/j.eururo.2016.02.029
10.1016/S1470-2045(21)00152-2
10.1016/S1470-2045(10)70275-8
10.1056/NEJMoa1613683
ContentType Journal Article
Copyright The Author(s) 2023
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023. BioMed Central Ltd., part of Springer Nature.
BioMed Central Ltd., part of Springer Nature 2023
Copyright_xml – notice: The Author(s) 2023
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023. BioMed Central Ltd., part of Springer Nature.
– notice: BioMed Central Ltd., part of Springer Nature 2023
DBID C6C
AAYXX
CITATION
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12885-023-11398-w
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic






Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 10
ExternalDocumentID oai_doaj_org_article_10619625828044718e74366ce2c048cc
PMC10504763
A765487396
10_1186_s12885_023_11398_w
GeographicLocations United States
Taiwan
GeographicLocations_xml – name: United States
– name: Taiwan
GrantInformation_xml – fundername: Chang Gung Memorial Hospital, Kaohsiung, Taiwan
  grantid: CPRPG8J0011, CPRPG8J0012
– fundername: ;
  grantid: CPRPG8J0011, CPRPG8J0012
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
ALIPV
CITATION
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c650t-718e1cb290010b2d0e98ba4c5973692b9ce6cf002cfbfb5e9f985b79548892f13
IEDL.DBID M48
ISSN 1471-2407
IngestDate Wed Aug 27 01:15:11 EDT 2025
Thu Aug 21 18:36:45 EDT 2025
Fri Sep 05 12:28:54 EDT 2025
Fri Jul 25 21:09:40 EDT 2025
Tue Jun 17 22:23:01 EDT 2025
Tue Jun 10 21:15:56 EDT 2025
Fri Jun 27 06:05:37 EDT 2025
Thu May 22 21:21:07 EDT 2025
Tue Jul 01 04:29:32 EDT 2025
Thu Apr 24 22:57:45 EDT 2025
Sat Sep 06 07:29:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Immune checkpoint inhibitors
Variant histology
Metastatic urothelial carcinoma
Real-world data
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c650t-718e1cb290010b2d0e98ba4c5973692b9ce6cf002cfbfb5e9f985b79548892f13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/10619625828044718e74366ce2c048cc
PMID 37715113
PQID 2865383068
PQPubID 44074
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_10619625828044718e74366ce2c048cc
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10504763
proquest_miscellaneous_2865780857
proquest_journals_2865383068
gale_infotracmisc_A765487396
gale_infotracacademiconefile_A765487396
gale_incontextgauss_ISR_A765487396
gale_healthsolutions_A765487396
crossref_primary_10_1186_s12885_023_11398_w
crossref_citationtrail_10_1186_s12885_023_11398_w
springer_journals_10_1186_s12885_023_11398_w
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-09-15
PublicationDateYYYYMMDD 2023-09-15
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-15
  day: 15
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC cancer
PublicationTitleAbbrev BMC Cancer
PublicationYear 2023
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References LM Nogueira (11398_CR14) 2022; 208
S Han (11398_CR27) 2021; 12
LN Diamantopoulos (11398_CR21) 2021; 19
W Jing (11398_CR36) 2020; 4
B Dietrich (11398_CR6) 2018; 38
MD Galsky (11398_CR3) 2011; 12
CN Sternberg (11398_CR4) 2006; 42
NJ Miller (11398_CR15) 2020; 204
J Bellmunt (11398_CR8) 2017; 376
M Moschini (11398_CR22) 2017; 14
A Necchi (11398_CR24) 2020; 77
A Necchi (11398_CR26) 2020; 77
DF Bajorin (11398_CR33) 1999; 17
11398_CR7
11398_CR12
MC Hsieh (11398_CR13) 2015; 10
Y Fu (11398_CR28) 2021; 14
V Genitsch (11398_CR32) 2019; 37
R Morinaga (11398_CR34) 2019; 12
N Lobo (11398_CR11) 2020; 6
A Minato (11398_CR17) 2022; 20
H Sung (11398_CR1) 2021; 71
A Necchi (11398_CR23) 2018; 36
N Almassi (11398_CR29) 2022; 129
T Powles (11398_CR9) 2021; 22
T Anraku (11398_CR31) 2023; 23
H Alnajar (11398_CR30) 2022; 8
M Deuker (11398_CR19) 2021; 19
MD Galsky (11398_CR10) 2020; 395
F Luo (11398_CR35) 2017; 12
A Fletcher (11398_CR2) 2011; 2011
J Gao (11398_CR25) 2020; 26
M Kobayashi (11398_CR16) 2022; 130
H von der Maase (11398_CR5) 2000; 18
A Minato (11398_CR20) 2017; 15
H Moch (11398_CR18) 2016; 70
References_xml – volume: 6
  start-page: 653
  issue: 4
  year: 2020
  ident: 11398_CR11
  publication-title: Eur Urol Focus
  doi: 10.1016/j.euf.2019.09.003
– volume: 14
  start-page: 1073
  year: 2021
  ident: 11398_CR28
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S290113
– volume: 130
  start-page: 226
  issue: 2
  year: 2022
  ident: 11398_CR16
  publication-title: BJU Int
  doi: 10.1111/bju.15510
– volume: 129
  start-page: 463
  issue: 4
  year: 2022
  ident: 11398_CR29
  publication-title: BJU Int
  doi: 10.1111/bju.15428
– volume: 23
  start-page: 38
  issue: 1
  year: 2023
  ident: 11398_CR31
  publication-title: BMC Urol
  doi: 10.1186/s12894-023-01210-z
– volume: 26
  start-page: 1845
  issue: 12
  year: 2020
  ident: 11398_CR25
  publication-title: Nat Med
  doi: 10.1038/s41591-020-1086-y
– volume: 204
  start-page: 63
  issue: 1
  year: 2020
  ident: 11398_CR15
  publication-title: J Urol
  doi: 10.1097/JU.0000000000000761
– volume: 14
  start-page: 651
  issue: 11
  year: 2017
  ident: 11398_CR22
  publication-title: Nat Rev Urol
  doi: 10.1038/nrurol.2017.125
– volume: 12
  start-page: 603
  issue: 2
  year: 2019
  ident: 11398_CR34
  publication-title: Case Rep Oncol
  doi: 10.1159/000502174
– volume: 20
  start-page: 499
  issue: 5
  year: 2022
  ident: 11398_CR17
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2022.05.001
– volume: 10
  start-page: e0129268
  issue: 6
  year: 2015
  ident: 11398_CR13
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0129268
– volume: 42
  start-page: 50
  issue: 1
  year: 2006
  ident: 11398_CR4
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2005.08.032
– volume: 36
  start-page: 3353
  issue: 34
  year: 2018
  ident: 11398_CR23
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.18.01148
– volume: 18
  start-page: 3068
  issue: 17
  year: 2000
  ident: 11398_CR5
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2000.18.17.3068
– ident: 11398_CR7
  doi: 10.1200/JCO.2019.37.7_suppl.451
– volume: 77
  start-page: 548
  issue: 4
  year: 2020
  ident: 11398_CR26
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2020.01.003
– volume: 12
  start-page: 734293
  year: 2021
  ident: 11398_CR27
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.734293
– volume: 77
  start-page: 439
  issue: 4
  year: 2020
  ident: 11398_CR24
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2019.10.026
– volume: 8
  start-page: a006151
  issue: 3
  year: 2022
  ident: 11398_CR30
  publication-title: Cold Spring Harb Mol Case Stud
  doi: 10.1101/mcs.a006151
– volume: 395
  start-page: 1547
  issue: 10236
  year: 2020
  ident: 11398_CR10
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30230-0
– volume: 19
  start-page: 60
  issue: 1
  year: 2021
  ident: 11398_CR19
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2020.07.011
– volume: 15
  start-page: e1063
  issue: 6
  year: 2017
  ident: 11398_CR20
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2017.07.008
– volume: 4
  start-page: e202000737
  issue: 1
  year: 2020
  ident: 11398_CR36
  publication-title: Life Sci Alliance
  doi: 10.26508/lsa.202000737
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  ident: 11398_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 17
  start-page: 3173
  issue: 10
  year: 1999
  ident: 11398_CR33
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1999.17.10.3173
– volume: 37
  start-page: 826
  issue: 11
  year: 2019
  ident: 11398_CR32
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2019.09.025
– volume: 12
  start-page: e0171701
  issue: 2
  year: 2017
  ident: 11398_CR35
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0171701
– volume: 2011
  start-page: 545241
  year: 2011
  ident: 11398_CR2
  publication-title: ISRN Urol
  doi: 10.5402/2011/545241
– volume: 208
  start-page: 813
  issue: 4
  year: 2022
  ident: 11398_CR14
  publication-title: J Urol
  doi: 10.1097/JU.0000000000002799
– volume: 38
  start-page: 342
  year: 2018
  ident: 11398_CR6
  publication-title: Am Soc Clin Oncol Educ Book
  doi: 10.1200/EDBK_201193
– volume: 19
  start-page: 144
  issue: 2
  year: 2021
  ident: 11398_CR21
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2020.10.002
– ident: 11398_CR12
  doi: 10.1111/bju.15984
– volume: 70
  start-page: 93
  issue: 1
  year: 2016
  ident: 11398_CR18
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.02.029
– volume: 22
  start-page: 931
  issue: 7
  year: 2021
  ident: 11398_CR9
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(21)00152-2
– volume: 12
  start-page: 211
  issue: 3
  year: 2011
  ident: 11398_CR3
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70275-8
– volume: 376
  start-page: 1015
  issue: 11
  year: 2017
  ident: 11398_CR8
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1613683
SSID ssj0017808
Score 2.4198833
Snippet Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face...
Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face...
While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited...
BackgroundWhile the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face...
Abstract Background While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma...
SourceID doaj
pubmedcentral
proquest
gale
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1
SubjectTerms Analysis
Biomedical and Life Sciences
Biomedicine
Bladder cancer
Cancer
Cancer Research
Carcinoma
Care and treatment
Chemotherapy
Development and progression
FDA approval
Genetic aspects
Genetic variation
Health Promotion and Disease Prevention
Hemoglobin
Immune checkpoint inhibitors
Medical prognosis
Medicine/Public Health
Metastases
Metastasis
Metastatic urothelial carcinoma
Monoclonal antibodies
Multivariate analysis
Oncology
Patient outcomes
Patients
Performance evaluation
Prognosis
Real-world data
Response rates
Statistical significance
Surgical Oncology
Survival
Survival analysis
Urothelial carcinoma
Variant histology
SummonAdditionalLinks – databaseName: Directory of Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4ikCBQaExAGi5unYx4KoClI5AJV6s2Jj06itU20SKn4Q_5MZx7sQKuDCcddjZdcz_jwTz3zD2DNTyKoydZO6Rri0qmrcc5a3ac6NKEtXicJSofDBe75_WL07qo9-afVFOWEzPfC8cDsUskh00jEyyCpCUotnHqc-VgaNzxhC30xm62Aq3h80IhPrEhnBdwZEYUGVyGWao8sj0ovFMRTY-i9j8uU8yd8uS8MZtHeDXY_OI-zOP_omu2L9LXb1IF6P32bfUelAGVe-J_ploOQMSgUizULvIJALB7CDrxgj46JC72GYEC7Q4KCfRrQ_O0DnIfKtDkAvauHMji2VHuHEaUU1W6dotmCoD5Hvz1pA2LQdvZqAjupNLKApmJPzvsMndP6404gbK5hrvb7dYYd7bz693k9jH4bUoP82prToudGFpABSF58zK4VuUcOyKbkstDSWG4fQapx2urbSSVHrhqjkhCxcXt5lW7739h4DnvO2zGxVFFai9tBdtbo2eJCWNrP4IWH5Wi3KRJJy6pVxqkKwIriaValQlSqoUl0k7MVmzvlM0fFX6Vek7Y0k0WuHL9DoVDQ69S-jS9hjshU116puQELtNpwiwFLyhD0NEkSx4SmH50s7DYN6-_HDQuh5FHI9_kvTxpIIXCti5VpIbi8kEQPMcnhttCpi0KCo5rgUGBKKhD3ZDNNMyqvztp9mGdordZMwsTD2xQItR3x3HHjI0TXPKjyfEvZyvS9-Pv3PGrj_PzTwgF0raDtTM496m22Nq8k-RPdw1I8CEvwABJhhkA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELbKVkJcEE8RKGAQEgeImqdjHxBqUauC1BUqVOrNSrxOG9Hayyah4gfxP5lxnK1CRY-7GSu7npnPHnvmG0LeqERkmcqLsC54HWZZDj6nWRnGTPE0rTOeaCwUPpyzg-Psy0l-skHmYy0MplWOmOiAemEVnpFvYwUlRFMR4x-XP0PsGoW3q2MLjdK3Vlh8cBRjt8gmQHIezcjm7t7869H6XqHgER9LZzjbbgGdOVYop2EMWyEeXk6WJ8fifx2rr-dP_nOJ6tam_Xvkrt9U0p3BCu6TDW0ekNuH_tr8IfkDxkAxE8tYpGWmmLSBKUKocWpr6kiHHQjSXxA7w2RTa2jbA4yAIVLbdzBHuqWNoZ6HtaV4gEsvdFdiSRIM7FdYy3UO5kwV9icy9qKkAKe6wSML2mAdiqZgIurH0jbwhsacNRXgyYoONWC_H5Hj_b3vnw5C358hVLCv60JY1nSsqkRgYFkli0gLXpWgeVGkTCSVUJqpGiBX1VVd5VrUgudVgRRzXCR1nD4mM2ONfkIoi1mZRjpLEi0yjuznusoVLLCpjjR8CEg8qkUqT16OPTTOpQtiOJODKiWoUjpVysuAvFuPWQ7UHTdK76K215JIu-2-sKtT6b1YYvwsIGKEMDXKcFnXsAFj2FRNARIqFZCXaCtyqGFdg4fcKRhGhqlgAXntJJB6w2Buz2nZt638_O1oIvTWC9UW_qUqfakEzBWydU0ktyaSgA1q-ng0WumxqZVXnhSQV-vHOBLz7Yy2_SCDvpIXAeETY59M0PSJac4cPzls2aMM1q2AvB_94urt_9fA05t_7DNyJ0FHxfYd-RaZdateP4cNYVe98F7-F4mcYcs
  priority: 102
  providerName: ProQuest
– databaseName: SpringerOpen Free (Free internet resource, activated by CARLI)
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgL4ikCBQxC4gAReTiOfSwrqoJUDkCl3qzY2G1E61SbhIofxP9kxvEGQgGJ48ZjRet5xzPfEPLMFJIxU9Wpq4VLGatA5yxv0pwbUZaOicJio_D-e753wN4dVocRJgd7YX69v88Ff9WD_RTYQ1ymOQQrIj2_TK5UYHhRmld8Nd8Y1CITm6aYP-5bOJ6Az3_RCl-sjPztejR4nd0b5HoMF-nOxN-b5JL1t8jV_Xghfpt8BzZTrLHyHQIuUyzHwOIf5CXtHA1wwsG80a-QFcMx0s7TfgQDASJGu3EAibM9bT2NCKs9xU-z9NQODTYbwcZxjV1aJyCo1ODkId-dNhQMpW3xYwRtscPEUmC--XLWtfCG1h-3GizFmk7dXd_ukIPdN59We2mcvJAaiNiGFByWzY0uJKaMuvicWSl0AzyVdclloaWx3DgwpsZppysrnRSVrhE8TsjC5eVdsuU7b-8RynPelJllRWElE4hrbnVlwHWWNrPwIyH5hi3KRFhynI5xokJ6IriaWKmAlSqwUp0n5MW852wC5fgn9Wvk9kyJgNrhAciZivqpMDOWkAtCApoxdNgWQiuO49IM2DhjEvIYZUVN3amzWVA7Ncecr5Q8IU8DBYJqeKzaOWrGvldvP35YED2PRK6Df2ma2AQBZ4U4XAvK7QUlaL1ZLm-EVkWr0yvsMi4F6IZIyJN5GXdiJZ233TjRoK5UdULEQtgXB7Rc8e1xQB6HYDxj4JES8nKjFz_f_ncO3P8_8gfkWoGKi4M6qm2yNaxH-xBCv0E_Cjr_A_70VKE
  priority: 102
  providerName: Springer Nature
Title The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
URI https://link.springer.com/article/10.1186/s12885-023-11398-w
https://www.proquest.com/docview/2865383068
https://www.proquest.com/docview/2865780857
https://pubmed.ncbi.nlm.nih.gov/PMC10504763
https://doaj.org/article/10619625828044718e74366ce2c048cc
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELf2ISFeEJ8iMIpBSDxAWJM4jv2AUFttGkibUKFSxYuVGGeL6JzRNIz9Qfyf3DlJp7CBxEuk1JdG8d39fGffByEvdCgZ03Hi54nIfcZi0DnDUz_gWkRRzkRoMFH48IgfzNiHeTzfIF27o3YCq2tdO-wnNVsu3vz8fvEOFP6tU3jBdyvAWIF5xpEfgEEj_PNNsu3OizCUj12eKiTCdagLAJDxVCHpkmiu_Y_eQuXq-V9F7auRlH8cp7pVav82udWal3TUyMMdsmHsXXLjsD1Av0d-gVhQjMmyJRZophi-gcFCyHta5tSVH3ZwSH-AFw3TTktLqxoABUSSlvUKJNRUtLC0rchaUdzKpadmlWJyEjxYLzGrawGCTTV2KrLlaUoBWE2Bmxe0wIwUQ0FY9LezsoA3FPakyABZlrTJBru4T2b7e58nB37bqcHXYOGtfFjgTKCzUKKLmYVfh0aKLAUZkEnEZZhJbbjOAXx1nuVZbGQuRZwlWGxOyDAPogdky5bWPCSUBzyNhoaFoZFMYB10k8UamBmZoYEbjwQdW5Ruy5hjN42Fcu6M4KphpQJWKsdKde6RV-tnzpoiHv-kHiO315RYgNv9UC6PVavPCj1pCb4jOKxDhgu8AVOMY3s1DZiotUeeoqyoJpt1DSNqlHD0ESPJPfLcUWARDotRPsdpXVXq_adpj-hlS5SX8JU6bZMmYK6wblePcqdHCSih-8Od0KpOyRRmJUcCnEbhkWfrYXwSI--sKeuGBvUmTjwiesLem6D-iC1OXKVyMN6HDFYwj7zu9OLy7X_nwKP_4tdjcjNEvcW-HvEO2Vota_MELMVVNiCbyTwZkO3x3tHHKdxN-GTgdl0GDhjgOh1_gessHP0Gmwtq3A
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4ikChRoE4gBREydx7ANC5VHt0m4P0Eq9mcR12ojWXjYbVv1BXPmNzOSxVajorcesx0k2M_N5xp4HIS81k3Gsk9QvUlH4cZyAzhme-SHXIoqKWDCDicKTXT7aj78cJAcr5E-fC4NhlT0mNkB96DTukW9gBiV4UwEX76c_fewahaerfQuNViy2zdkCXLbq3fgT8PcVY1uf9z6O_K6rgK_BGpn7AMYm1DmT6A7l7DAwUuQZvK9MIy5ZLrXhugCg0EVe5ImRhRRJnmJhNCFZEUZw32vkeoxHjKA_6cHSwQtTEYg-MUfwjQqwX2D-c-SHYGgJfzFY_JoeARdXgovRmf8c0TYr39YdcrszWelmK2N3yYqx98iNSXcof5_8BlGjGOdlHRZ9phgSggFIKE_UFbQpadxALP0FnjmwkjpLqxpACsScunoOHDAVLS3tqrxWFLeH6amZZ5jwBBPrGWaKnYCyUI3dj6w7zSiAtSlxQ4SWmOViKAig_jF1JTyhtMdlDmg1o22G2dkDsn8lfHpIVq2z5hGhPORZFJiYMSNjgbXVTZ5oWL4jExi48EjYs0XprjQ6dug4UY2LJLhqWamAlaphpVp45M1yzrQtDHIp9Qfk9pISi3o3P7jZkeowQqF3LsEfBSc4iNFoMGDecWzZpgFntfbIOsqKajNkl9CkNlOOfmckuUdeNBRY2MNi5NBRVleVGn_7OiB63REVDv6lzrpEDPhWWAtsQLk2oATk0cPhXmhVh3yVOtdTjzxfDuNMjOazxtUtDepKknpEDIR98IGGI7Y8bqqfg0MQxLAqeuRtrxfnT_8_Bx5f_rLr5OZob7Kjdsa720_ILYZKi41CkjWyOp_V5imYnvP8WaPvlHy_aoD5C9yRl60
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBUXxFMECjUIiQNEzcNx7OPyWLVAKwSs1JuVuHYbtXVWm4SKH8T_ZMZJFkIBiePGY0XreXni-T4T8kwnkjGd5aHNhQ0Zy8DnDC_CmGuRppaJxCBQeP-A7y7Yu8Ps8BcUv-92H48ke0wDsjS5dmd5ZHsXF3yngagqEFmchjFsYUR4cZVcY5CrsalrkczW5wi5iMQIlfnjvEk68qz9l2Pz5X7J3w5NfS6a3yQ3hk0knfVav0WuGHebbO4Px-R3yHdQPsXOK1cjDTPFJg1sCUIN09pSTzLsgx79CrUyLC6tHW06CBtgeLTuWlgS09DK0YF3taH4wZaem7ZACBJM7FaI3ToD86Ua7yNy9XlBIXyaCj9R0ApxJ4aCSejTZV3BGyp3UpUQP1a0x3x9u0sW87dfXu-Gw30MoYZ9XBtCGjOxLhOJhWSZHEVGirIATcs85TIppTZcWwix2pa2zIy0UmRljpRyQiY2Tu-RDVc7c59QHvMijQxLEiOZQLZzU2YaEmpqIgM_AhKPalF6ICvHOzPOlC9aBFe9KhWoUnlVqouAvFjPWfZUHf-UfoXaXksizbZ_UK-O1eC1CutlCRUilKURwzRuYMPF8RI1DZFP64Bso62oHrO6DhZqlnOsBFPJA_LUSyDVhsNenuOiaxq19_nTROj5IGRr-Je6GKARsFbIzjWR3JpIQizQ0-HRaNUQixqF2ONUQGkoAvJkPYwzsb_OmbrrZdBXsjwgYmLskwWajrjqxPORwxY9YpCnAvJy9Iufb_-7Bh78n_g22fz4Zq4-7B28f0iuJ-jDeJNHtkU22lVnHsHesC0fe_f_AfTWX_Y
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+prognostic+significance+of+histologic+variant+on+survival+outcomes+in+patients+with+metastatic+urothelial+carcinoma+receiving+immune+checkpoint+inhibitor+therapy&rft.jtitle=BMC+cancer&rft.au=Tsai%2C+Tsung-Han&rft.au=Su%2C+Po-Jung&rft.au=Huang%2C+Shih-Yu&rft.au=Kuo%2C+Ming-Chun&rft.date=2023-09-15&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-023-11398-w&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12885_023_11398_w
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon